Data from NIAGARA supported the FDA’s approval of neoadjuvant durvalumab in combination with gemcitabine and cisplatin, ...
Operationalizing Subcutaneous Checkpoint Inhibitors in Practice. Implementing subcutaneous checkpoint inhibitors requires ...
Data from a large prospective study identified male and older patients as being more likely to develop CIP and 34% of cases ...
Chemotherapy-induced myelosuppression (CIM) significantly impacts quality of life for patients with cancer and leads to ...
A preliminary analysis of patient-reported outcomes for emotional functioning (EF) in patients with solid tumors revealed ...
Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI ...
On this episode of Onc Nurse On Call, Kristin Daly, MSN, ANP-BC, AOCNP, discusses practical cancer care strategies in the age ...
Buparlisib combined with paclitaxel failed to improve overall survival vs paclitaxel alone for patients with PD-1/PD-L1–pretreated HNSCC. The combination of buparlisib and paclitaxel did not show an ...
Patient-reported outcomes showed that health-related QOL stayed at baseline for patients with HRRM-positive mHSPC receiving a niraparib regimen. Health-related quality of life (HR-QOL) remained at ...
Atezolizumab Subcutaneous Data and Implementation Considerations. The subcutaneous formulation of atezolizumab (PD-L1 inhibitor) received approval approximately 1 year ago based o ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback